Evaluation of the efficacy of Silymarin in patients with COVID-19

INTERVENTION: Intervention 1: Intervention group: patients with COVID‐19 in addition to a standard regimen(Includes dexamethasone and remdesivir and in case of suspected bacterial superinfection with parental antibiotics) will receive Silymarin nanomicelles orally 70 mg from Nano Exir Sina Company/ three times a day. Intervention 2: Control group: 25 patients will receive only standard regimen of COVID‐2019(Includes dexamethasone and remdesivir and in case of suspected bacterial superinfection with parental antibiotics) + The placebo is made by Nano Sina Elixir Company, which is exactly the same in terms of appearance, taste and dose. CONDITION: Patients with COVID‐2019. ; COVID‐19 U07.01 PRIMARY OUTCOME: Time to clinical improvement. Timepoint: 28 days from study enrollment. Method of measurement: Instrument name: Ordinal Scale for Clinical Improvement. The Sequential Clinical Recovery Scale is used by the World Health Organization for Covid patients. This scale contains 8 scores. the scores include: 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities 3. Hospitalized, not requiring supplemental oxygen 4. Hospitalized, requiring supplemental oxygen by mask or nasal prongs 5. Hospitalized, on non‐invasive ventilation or high flow oxygen devices 6. Hospitalized, on invasive mechanical ventilation 7. Hospitalized, on invasive mechanical ventilation + additional organ support (pressors, RRT, ECMO) 8. Death. SECONDARY OUTCOME: Length of Hospitalization. Timepoint: Hospitalization time at the discretion of the physician. Method of measurement: days. Mortality. Timepoint: 28 days from study enrollment. Method of measurement: All cause mortality (ACM). INCLUSION CRITERIA: Patients with clinical or laboratory diagnosis of covid‐19 should be hospitalized based on the opinion of a specialist physician. age between 18 to 75 Signing an informed consent form